Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Net Income (2023 - 2025)

Historic Net Income for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to -$15.8 million.

  • Compass Therapeutics' Net Income fell 2923.44% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.1 million, marking a year-over-year decrease of 4154.73%. This contributed to the annual value of -$56.6 million for FY2024, which is 3325.41% down from last year.
  • According to the latest figures from Q3 2025, Compass Therapeutics' Net Income is -$15.8 million, which was down 2923.44% from -$21.1 million recorded in Q2 2025.
  • In the past 5 years, Compass Therapeutics' Net Income registered a high of -$7.8 million during Q1 2023, and its lowest value of -$21.1 million during Q2 2025.
  • For the 3-year period, Compass Therapeutics' Net Income averaged around -$13.5 million, with its median value being -$13.1 million (2024).
  • Its Net Income has fluctuated over the past 5 years, first tumbled by 1594.25% in 2024, then crashed by 6110.43% in 2025.
  • Compass Therapeutics' Net Income (Quarter) stood at -$13.4 million in 2023, then decreased by 23.55% to -$16.6 million in 2024, then grew by 4.57% to -$15.8 million in 2025.
  • Its Net Income stands at -$15.8 million for Q3 2025, versus -$21.1 million for Q2 2025 and -$16.6 million for Q1 2025.